Genetic association of type 2 diabetes and antidiabetic drug target with skin cancer.

ABSTRACT:

Background

Several observational studies have suggested that type 2 diabetes (T2D) is a risk factor for skin cancer, and antidiabetic drugs may reduce skin cancer risk. Nevertheless, the findings remain ambiguous. This Mendelian randomization (MR) study aimed to investigate the causal association of T2D with skin cancer and evaluate the potential impact of antidiabetic drug targets on skin cancer.

Methods

Genetic variants associated with glycated hemoglobin (HbA1c), Type 2 Diabetes (T2D), and antidiabetic drug targets (KCNJ11, ABCC8, PPARG, INSR, GLP1R, SLC5A2, and DPP4) were sourced from genome-wide association studies in the UK Biobank and the DIAMANTE consortium. Genetic summary statistics on skin cancer were obtained from the FinnGen consortium. MR analysis was primarily

SUBMITTER: Zhao J 

PROVIDER: S-EPMC11617162 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature